Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

Asia Regenerative Medicine Raises Pre-Series A+ Funding for Bioartificial Organs

Fineline Cube Feb 8, 2023

Shenzhen-based Asia Regenerative Medicine (ARM) has reportedly raised “tens of millions” of renminbi in a...

Company Deals

Beijing Smart Beam Raises Series A+ Funding for CT X-Ray Tube Development

Fineline Cube Feb 8, 2023

Beijing Smart Beam Technology, a leading vacuum electronic device maker, has reportedly raised “tens of...

Company Deals

Asieris Partners with ReviR Therapeutics for Urogenital Cancer Research

Fineline Cube Feb 8, 2023

China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has struck a...

Company

Siemens Healthineers Reports Q1 Revenue Drop Amid COVID-19 Impact

Fineline Cube Feb 7, 2023

Germany-based medical device giant Siemens Healthineers AG has released its fiscal year 2023 Q1 financial...

Company

Astellas Pharma Reports Strong Q3 Results with 17.3% Revenue Growth

Fineline Cube Feb 7, 2023

Japan-based Astellas Pharma Inc. (TYO: 4503) has released its financial report for Q3 of its...

Company Drug

Fujian Cosunter’s HBV Therapy GST-HG141 Begins Phase II Trial

Fineline Cube Feb 7, 2023

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the first patient enrollment and...

Company Drug

Harbour BioMed’s Anti-CCR8 Monoclonal Antibody HBM1022 Receives FDA IND Approval

Fineline Cube Feb 7, 2023

Harbour BioMed (HBM), which operates out of the Netherlands, the United States, and Suzhou, China,...

Company Drug

Eli Lilly’s Tirzepatide Achieves Primary Endpoints in Chinese Obesity Study

Fineline Cube Feb 7, 2023

US major Eli Lilly (NYSE: LLY) has announced that the Phase III SURMOUNT-CN study for...

Company Deals

Lifetech Partners with Jenscare for Structural Heart Disease Devices

Fineline Cube Feb 7, 2023

China-based Lifetech Scientific Corporation (HKG: 1302) has announced a partnership agreement with compatriot firm Jenscare...

Company Drug

Gracell’s CAR-T Therapy GC012F Receives FDA IND Approval

Fineline Cube Feb 7, 2023

Shanghai-based biotech Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the US...

Company

Gilead Sciences Reports Q4 and Full-Year 2022 Financial Results

Fineline Cube Feb 6, 2023

US major Gilead Sciences, Inc. (NASDAQ: GILD) last week reported Q4 and full-year 2022 financial...

Company Drug

Sanofi Reports Strong Q4 and Full-Year 2022 Financials with 7% Growth

Fineline Cube Feb 6, 2023

France’s Sanofi (EPA: SAN) released its financial report last week, showing turnover during Q4 and...

Company

Sanner Group Prepares to Open Second Manufacturing Facility in China

Fineline Cube Feb 6, 2023

Germany-based Sanner Group, a specialist in medical devices and pharma packaging, has announced plans to...

Company

Insilico Medicine Opens AI Biotech Research Center in Abu Dhabi

Fineline Cube Feb 6, 2023

China-based AI-powered drug discovery firm Insilico Medicine has revealed the opening of an AI-powered biotechnology...

Digital Medical Device

Vertex’s MoDAS System Gains NMPA Approval for Movement Disorder Assessment

Fineline Cube Feb 6, 2023

China-based Vertex has announced receiving medical device approval from the National Medical Products Administration (NMPA)...

Company Digital

BeiGene Launches Mental Health Program for Cancer Patients

Fineline Cube Feb 6, 2023

China-based biotech BeiGene (Nasdaq: BGNE; HKG: 6160; SHA: 688235) has announced the launch of a...

Company Deals

AnHeart Therapeutics Partners with Guardant Health for Taletrectinib Diagnostics

Fineline Cube Feb 6, 2023

Sino-US biopharma AnHeart Therapeutics and US precision oncology firm Guardant Health Inc. (NASDAQ: GH) have...

Company Drug

Grand Pharma’s TLX101 Accepted for NMPA Review for Glioblastoma Treatment

Fineline Cube Feb 6, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that an Investigational New Drug (IND)...

Company Deals

Forlong Biotechnology Secures Series A Funding for Protein Drug Development

Fineline Cube Feb 6, 2023

Forlong Biotechnology, a synthetic immunology-driven protein drug developer based in Suzhou, has reportedly raised upwards...

Company Deals

Zhimeng Biopharma Signs Global Licensing Deal with GSK for TLR8 Agonist CB06

Fineline Cube Feb 6, 2023

Shanghai Zhimeng Biopharma Inc. has announced the signing of a global licensing agreement with UK...

Posts pagination

1 … 619 620 621 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.